News Update

Retatrutide: The Triple Agonist That Could Redefine Obesity Treatment

Retatrutide is Eli Lilly's experimental triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show unprecedented weight loss of up to 24%. Here's what the research reveals.

Metabolic Peptides13 min readDecember 18, 2025

The Next Evolution in Weight Loss Peptides

If you've been following the GLP-1 revolution—Ozempic, Wegovy, Mounjaro—prepare for what could be the next major advancement: retatrutide. Developed by Eli Lilly, this experimental peptide doesn't just target one or two receptors; it hits three simultaneously.

What Is Retatrutide?

Retatrutide (LY-3437943) is a triple glucagon hormone receptor agonist, meaning it activates:

  1. GLP-1 receptors (like semaglutide)
  2. GIP receptors (like tirzepatide)
  3. Glucagon receptors (the new addition)

This triple mechanism represents a significant evolution from current therapies:

  • Semaglutide (Ozempic/Wegovy): GLP-1 only
  • Tirzepatide (Mounjaro/Zepbound): GLP-1 + GIP
  • Retatrutide: GLP-1 + GIP + Glucagon

Phase 3 Trial Results (December 2025)

The TRIUMPH-4 trial results announced in December 2025 showed remarkable outcomes:

Weight Loss

  • Up to 71.2 lbs average weight loss in the highest dose group
  • Percentage-wise, up to 24.2% mean weight loss after 48 weeks

Additional Benefits

  • Substantial relief from osteoarthritis pain
  • Significant improvements in cardiometabolic markers
  • 72% of participants with prediabetes reverted to normal blood sugar

How Does the Triple Mechanism Work?

GLP-1 Component

  • Reduces appetite and food intake
  • Slows gastric emptying
  • Improves insulin secretion

GIP Component

  • Enhances insulin sensitivity
  • May reduce some GI side effects of GLP-1
  • Contributes to fat metabolism

Glucagon Component (The Game-Changer)

This is where retatrutide differs most significantly:

  • Increases energy expenditure: Glucagon promotes thermogenesis
  • Enhances fat burning: Directly stimulates lipolysis
  • Liver benefits: The liver is rich in glucagon receptors, unlike GLP-1/GIP receptors

The liver connection is particularly important. While GLP-1 and GIP show benefits in fatty liver disease (NASH), the liver has no GLP-1 or GIP receptors—but is rich in glucagon receptors. This makes retatrutide especially attractive for metabolic liver disease.

Comparison to Existing Treatments

DrugMechanism~Weight Loss (48 weeks)Status
SemaglutideGLP-1~15%Approved
TirzepatideGLP-1 + GIP~20%Approved
RetatrutideGLP-1 + GIP + Glucagon~24%Phase 3

Beyond Weight Loss

Eli Lilly is studying retatrutide across multiple conditions:

  • Type 2 diabetes: 16.9% weight loss and 2.2% HbA1c improvement in trials
  • Knee osteoarthritis: Significant pain relief (TRIUMPH-4)
  • Obstructive sleep apnea: Ongoing trials
  • Chronic low back pain: Ongoing trials
  • Cardiovascular outcomes: Long-term studies underway
  • Metabolic liver disease (MASLD): Particularly promising given glucagon's liver effects

Safety Considerations

GI Side Effects

Like other GLP-1 drugs, retatrutide causes gastrointestinal effects:

  • Nausea (most common)
  • Diarrhea
  • Vomiting
  • Constipation

Most side effects were mild to moderate and occurred during dose escalation.

The Glucagon Question

One concern with adding glucagon is its potential to raise blood sugar (glucagon is the hormone that tells the liver to release glucose). However, trials show the GLP-1 and GIP components appear to counterbalance this effect, resulting in net improvements in glucose control.

Timeline to Approval

Retatrutide is still in Phase 3 trials. Based on typical timelines:

  • Phase 3 completion: 2026
  • Potential FDA submission: Late 2026
  • Possible approval: 2027 at the earliest

This assumes trials continue showing positive results and no unexpected safety signals emerge.

What This Means for the Future

Retatrutide represents the logical next step in incretin-based therapies. The addition of glucagon receptor agonism could offer:

  1. Greater weight loss than current options
  2. Better liver outcomes due to direct hepatic effects
  3. Increased energy expenditure through thermogenesis
  4. Potential for treating a broader range of metabolic conditions

Conclusion

Retatrutide may represent the most significant advancement in obesity pharmacotherapy since semaglutide. The triple agonist approach—targeting GLP-1, GIP, and glucagon receptors simultaneously—could offer unprecedented efficacy for weight management and metabolic disease.

However, we await full Phase 3 data, long-term safety information, and regulatory review. For now, approved options like semaglutide and tirzepatide remain the standard of care.

This article is for educational purposes only. Retatrutide is an investigational drug not yet approved for any use.

Related Peptides

SemaglutideTirzepatideRetatrutide
DSC

Dr. Sarah Chen

PhD, BiochemistryResearching Peptides Editorial Team

Dr. Chen specializes in peptide biochemistry and has contributed extensively to research literature reviews. Her work focuses on translating complex scientific findings into accessible content for researchers and enthusiasts.

Related Articles

Research9 min

Ecnoglutide: The First 'Biased' GLP-1 Just Got Approved — And the Nausea Numbers Are Striking

On March 6, 2026, China's NMPA approved ecnoglutide for chronic weight management — the world's first cAMP-biased GLP-1 receptor agonist to reach market. The Phase 3 numbers are remarkable not because the weight loss is record-breaking (it isn't), but because the nausea rate at the top dose was 12.7% versus 9.9% on placebo. That's a different shape of side-effect curve than anything we've seen from a GLP-1 before, and it's the first real-world test of biased agonism as a drug-design strategy.

Metabolic Peptides
Research10 min

BRP: Stanford's 12-Amino-Acid 'Natural Ozempic' That Skips the Nausea

A Stanford team used a computational pipeline called Peptide Predictor to comb through 2,683 hypothetical human peptide fragments and pull out a 12-mer they named BRP. In mice and minipigs it cut food intake by up to 50% in an hour and stripped fat without touching lean mass — and it didn't go anywhere near the GLP-1 receptor. Here's what the Nature paper actually shows, what it doesn't, and why it might matter even more than another incretin.

Metabolic Peptides
Research14 min

Pemvidutide: The GLP-1/Glucagon Peptide That Just Got FDA Breakthrough Status for MASH

In January 2026, the FDA granted Altimmune's pemvidutide Breakthrough Therapy Designation for MASH after Phase 2b data showed 54.7% liver fat reduction, meaningful fibrosis improvement, and a lipid profile unlike anything else in the GLP-1 class. Here's what the data actually shows—and why Phase 3 could reshape fatty liver treatment.

Metabolic Peptides